Song Chunjiao, Chen Huan
1Medical Research Center, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), No. 568 Zhongxing Bei Road, Shaoxing, 312000 Zhejiang People's Republic of China.
2Zhejiang Institute of Microbiology (Key Laboratory of Microorganism Technology and Bioinformatics Research of Zhejiang Province), Hangzhou, Zhejiang China.
Cancer Cell Int. 2018 Nov 12;18:177. doi: 10.1186/s12935-018-0672-2. eCollection 2018.
Prostate cancer is a major malignancy in males. - is a high-frequency fusion gene expressed in prostate cancer and plays a vital role in carcinogenesis. Recent studies showed that - is a potential predictive biomarker for prostate cancer. However, the predictive value of - fusion is yet unclear.
A total of 76 relevant articles, published from 2015 to 2017, were obtained from PubMed, Web of Science, EMBASE, Scopus, the Cochrane Library, and CNKI databases to investigate the predictive significance of - fusion in prostate cancer. Pooled odds ratio (ORs) with 95% confidence intervals (CIs) were calculated to estimate the correlation between - fusion gene and tumor features.
The pooled or stratified analysis showed that the - fusion gene had a highly predictive potential. First, - fusion was associated with T-stage at diagnosis (T3-4 vs. T1-2 OR: 1.40; 95% CI 1.33-1.48) and metastasis (M1 vs. M0 OR: 1.35; 95% CI 1.02-1.78) but not with biochemical recurrence or prostate cancer-specific mortality. Furthermore, the subgroup analysis found that the - fusion gene was correlated with Gleason (G) scores, and the fusion was common in prostate cancer with G ≤ 7. Additionally, the meta-analysis demonstrated that the fusion was likely to occur in young patients (> 65 vs. ≤ 65 OR: 0.68; 95% CI 0.52-0.89), in patients with high PSA levels (> 10 vs. ≤ 10 OR: 1.30; 95% CI 1.21-1.38), and in patients with peripheral involvement (positive vs. negative OR: 1.17; 95% CI 1.08-1.28), while not associated with tumor volume. Finally, the subgroup analysis of different fusion types demonstrated that the deletion-type fusion was significantly associated with the malignant degree of prostate cancer (pooled OR: 5.67; 95% CI 2.85-11.28). Moreover, the deletion-type was common in Africa patients, followed by Caucasian patients, and no significant difference was observed in the incidence of different fusion types in the Asian population.
The meta-analysis findings suggested that the - fusion gene might be a predictive marker for prostate cancer patients, and might be valuable for assessing the characteristics of prostate cancer for individualized treatment and prognosis evaluation.
前列腺癌是男性主要的恶性肿瘤。- 是一种在前列腺癌中表达的高频融合基因，在致癌过程中起关键作用。近期研究表明 - 是前列腺癌潜在的预测生物标志物。然而，- 融合的预测价值尚不清楚。
从PubMed、Web of Science、EMBASE、Scopus、Cochrane图书馆和CNKI数据库中获取2015年至2017年发表的76篇相关文章，以研究 - 融合在前列腺癌中的预测意义。计算合并比值比（OR）及95%置信区间（CI），以评估 - 融合基因与肿瘤特征之间的相关性。
合并或分层分析显示 - 融合基因具有高度预测潜力。首先，- 融合与诊断时的T分期（T3 - 4 vs. T1 - 2，OR：1.40；95% CI 1.33 - 1.48）和转移（M1 vs. M0，OR：1.35；95% CI 1.02 - 1.78）相关，但与生化复发或前列腺癌特异性死亡率无关。此外，亚组分析发现 - 融合基因与Gleason（G）评分相关，且该融合在G≤7的前列腺癌中常见。另外，荟萃分析表明该融合可能发生在年轻患者（>65岁 vs.≤65岁，OR：0.68；95% CI 0.52 - 0.89）、前列腺特异性抗原（PSA）水平高的患者（>10 vs.≤10，OR：1.30；95% CI 1.21 - 1.38）以及有外周侵犯的患者（阳性 vs. 阴性，OR：1.17；95% CI 1.08 - 1.28）中，而与肿瘤体积无关。最后，不同融合类型的亚组分析表明缺失型融合与前列腺癌的恶性程度显著相关（合并OR：5.67；95% CI 2.85 - 11.28）。此外，缺失型在非洲患者中常见，其次是白种人患者，亚洲人群中不同融合类型的发生率未观察到显著差异。
荟萃分析结果表明 - 融合基因可能是前列腺癌患者的预测标志物，对于评估前列腺癌特征以进行个体化治疗和预后评估可能具有重要价值。
